Year : 2022  |  Volume : 15  |  Issue : 2  |  Page : 147--153

Feasibility, safety, and efficacy of iron bioresorbable scaffold in neonates with duct-dependent pulmonary circulation


Marhisham Che Mood1, Khalil Ahmad Niazy1, Mazeni Alwi1, Hasri Samion1, Koh Ghee Tiong2, Sivakumar Sivalingam1, Deyuan Zhang3 
1 Paediatric and Congenital Heart Centre, Institut Jantung Negara (National Heart Institute), Kuala Lumpur, Malaysia
2 Department of Paediatric, Hospital Serdang, Selangor, Malaysia
3 National and Local Joint Engineering Laboratory of Interventional Medical Biotechnology and System, Lifetech Scientific (Shenzhen) Co., Ltd., Shenzhen, China

Correspondence Address:
Dr. Marhisham Che Mood
Paediatric & Congenital Heart Centre, Institut Jantung Negara (National Heart Institute), Kuala Lumpur
Malaysia

Introduction: Bioresorbable stent has the theoretical advantage in the pediatric age group; however, experience in the literature is very limited. Objectives: This pilot study sought to evaluate the feasibility, safety, and performance of iron bioresorbable scaffold (IBS Angel™) as short-term palliation in lesions with noncomplex patent ductus arteriosus (PDA). Materials and Methods: Nine neonates with duct dependent but dual-source pulmonary blood flow (PBF) were included. Major stent-related complications, in-hospital course, stent patency up to 6 months, and unplanned re-interventions were studied, as well the percentage of stent material resorbed in patients in whom the stents were explanted at the surgery. Results: IBS Angel™ was successfully implanted in all nine patients (mean weight range 3.4 ± 0.4 kg). Six were pulmonary atresia with an intact ventricular septum and 1 critical pulmonary stenosis patients where PDA stenting was done together or after balloon dilation. The mean procedure and fluoroscopy times were 89 ± 39 min and 16.3 ± 6.9 min, respectively. There were no major complications such as stent thrombosis or embolization and there were no in-hospital deaths. Post procedure overshunting and prolonged ventilatory support was a prominent feature. The median ventilation days was 3 (1–11 days). One patient died after 1 month due to respiratory syncytial virus pneumonia at the referring hospital. At 6 months follow-up, four had patent stents and four had blocked or restrictive stent flow. One patient received re-stenting at 4 months for restrictive stent flow. In three patients where microcomputed tomography of explanted stent was available, resorption of iron was 15% at 6 months and >65% at 16 months. Conclusions: Ductal stenting with IBS Angel™ is feasible and safe in selected patients. Because of early luminal loss, its use may be recommended for lesions with dual-source PBF with noncomplex PDA morphology that requires a short duration of palliation.


How to cite this article:
Mood MC, Niazy KA, Alwi M, Samion H, Tiong KG, Sivalingam S, Zhang D. Feasibility, safety, and efficacy of iron bioresorbable scaffold in neonates with duct-dependent pulmonary circulation.Ann Pediatr Card 2022;15:147-153


How to cite this URL:
Mood MC, Niazy KA, Alwi M, Samion H, Tiong KG, Sivalingam S, Zhang D. Feasibility, safety, and efficacy of iron bioresorbable scaffold in neonates with duct-dependent pulmonary circulation. Ann Pediatr Card [serial online] 2022 [cited 2022 Nov 28 ];15:147-153
Available from: https://www.annalspc.com/article.asp?issn=0974-2069;year=2022;volume=15;issue=2;spage=147;epage=153;aulast=Mood;type=0